When announcing the deal on Jul. 6, 2023, Thermo Fisher said that real-world evidence is a high growth market segment as pharmaceutical and biotechnology customers, as well as regulating bodies, are increasingly looking to monitor and evaluate the safety of approved therapies and examine their effectiveness and value in the post approval setting.

“We are very excited to welcome our new CorEvitas colleagues to Thermo Fisher,” said Marc N. Casper, Thermo Fisher’s chairman, president and CEO of. “CorEvitas expands our clinical research business with highly complementary real-world evidence solutions, which is an increasingly important area and will help to enhance decision-making as well as the time and cost of drug development.”

CorEvitas will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.